Novo Says May Take Years to Comply With FDA Request

Feb. 11 (Bloomberg) -- Novo Nordisk A/S Chief Executive Officer Lars Rebien Soerensen discusses the U.S. Food and Drug Administration's decision not to approve the insulin maker's Tresiba diabetes treatment, saying more data on heart safety is needed. He talks from Copenhagen with Francine Lacqua on Bloomberg Television's "On the Move." (Source: Bloomberg)

JPM's Kemery Has Concerns About OPEC Exit Strategy
10:20 - Ebele Kemery, head of energy investing at JPMorgan, and Bloomberg's David Wethe, discuss a reported extension of OPEC production cuts and what their lack of an exit strategy means to markets. They speak on "Bloomberg Daybreak: Americas." (Source: Bloomberg)
  • Former Ex-Im Chairman Says Border Tax Not Happening
  • Kganyago Says South Africa Rate Unchanged at 7%
  • U.S. Weekly Jobless Claims Little-Changed at 234,000